I
ICON
Global clinical research to accelerate drug commercialisation
About ICON
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times.
We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1990
- Headquarters
- Ireland
- Listing
- IPO 1998
- Employees
- 35,458
- Open positions
- 330
- Dealroom signal
- 84.5/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Medical Research, Medical & Healthcare, EIT KIC Partners, research institute
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 7 companies, latest Feb 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Aug 2026 | $2.1B | — | Undisclosed | ↗ |
| POST IPO DEBT✓Debt | Apr 2024 | $2B | — | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for ICON is 500K monthly website visits, up 0% over the last three months. ICON's team grew 226.9% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
HumanFirstBoston, United StatesElektra Labs is building a search platform to find, select, and eventually develop new digital biomarkers and sensors
$12Mvaluation
PRA Health SciencesRaleigh, United StatesDedicated to the future of clinical development and to every life it saves
$12Bvaluation
MedPass InternationalParis, FranceThe leading Europe Medical Device CRO,Regulatory and Reimbursement Consultancy specialized, in medical device development and market access
→
MolecularMDPortland, United StatesThe development of molecular diagnostic tests
$24Mvaluation
Mapi GroupLyon, FranceService provider to the global healthcare industry
→
OL
Oxford Outcomes LimitedOxford, United KingdomSpecialist services in the fields of patient reported outcomes (pro), health economics, epidemiology
→
TI
Timaq Medical ImagingZurich, SwitzerlandSwiss based provider of advanced imaging services to pharmaceutical and biotech firms
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Enterprise Ireland
Other known investors1 additional known investor
US Biomedical Advanced Research and Development Authority
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about ICON on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See ICON’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.